HGH (Somatropin)

WHAT IT IS

Somatropin is a recombinant form of human growth hormone, manufactured using DNA technology to match the amino acid sequence of the hormone naturally secreted by the anterior pituitary gland. It acts on receptors throughout the body, largely by stimulating the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of its downstream effects on growth, metabolism and tissue maintenance.

It has been an approved prescription medicine for decades and is manufactured by several pharmaceutical companies under various brand names, administered by injection under medical supervision.

FDA status: Somatropin is FDA-approved for a defined set of conditions, including growth hormone deficiency in children and adults, certain pediatric growth disorders and specific wasting syndromes; distribution or use for anti-aging, bodybuilding or general performance purposes is not an approved use and is restricted by federal law.

WHAT RESEARCHERS STUDIED IT FOR

Decades of clinical research, spanning approved and off-label interest, have examined:

• Growth restoration in children with growth hormone deficiency or certain genetic growth disorders
• Metabolic and body composition effects in adults with diagnosed growth hormone deficiency
• Muscle wasting associated with HIV/AIDS and short bowel syndrome
• Effects on body composition, strength and quality of life in healthy older adults with age-related decline in growth hormone output

PROPOSED BIOLOGICAL MECHANISMS

Growth hormone binds receptors in the liver and other tissues, stimulating IGF-1 production, which drives cell growth, protein synthesis and lipolysis. It also has direct effects on fat and glucose metabolism independent of IGF-1.

In growth hormone deficiency, replacing the hormone restores signaling that is otherwise insufficient, supporting normal growth in children and normalized body composition and metabolism in adults.

In healthy adults with naturally declining growth hormone output due to aging, the same signaling pathway is intact but hormone levels are lower than in youth, which is the rationale researchers have tested, though the body is not in a deficient or diseased state in that context.

AREAS OF RESEARCH INTEREST

• Whether modest body composition changes seen with growth hormone in healthy older adults translate into meaningful functional benefit
• How to weigh documented adverse effects against the limited functional gains observed in non-deficient adults
• Long-term cancer and mortality risk associated with sustained IGF-1 elevation
• Whether lower, more physiologic dosing strategies can reduce adverse effects while preserving any benefit

WHAT THE EVIDENCE CURRENTLY SUGGESTS

In approved indications such as pediatric and adult growth hormone deficiency, decades of controlled trials support somatropin's efficacy for restoring growth and improving body composition and quality of life, and it is considered standard of care under medical supervision.

In healthy older adults without growth hormone deficiency, a landmark randomized controlled trial (Blackman et al., JAMA 2002) and a systematic review (Liu et al., Annals of Internal Medicine 2007) found that growth hormone administration modestly increased lean body mass and decreased fat mass, but did not consistently improve strength, endurance or other functional outcomes, and was associated with a high rate of adverse effects.

Documented adverse effects in these research settings and in broader clinical use include fluid retention, joint pain and swelling, carpal tunnel syndrome, increased insulin resistance and new-onset glucose intolerance or diabetes, and gynecomastia in men. Long-term cancer risk with sustained IGF-1 elevation remains an area of ongoing monitoring and research.